Taiwan Liposome Company Ltd ADR (TLC)

7  0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

Taiwan Liposome Company Ltd ADR

NASDAQ:TLC (9/28/2021, 7:00:01 PM)

7

0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorN/A
GICS IndustryN/A
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap294.54M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

TLC Daily chart

Company Profile

Taiwan Liposome Company Ltd. is a specialty pharmaceutical company. It focuses on development and commercialization of novel nanomedicines designed to target unmet medical need in pain management, ophthalmology and oncology. The company's product pipeline consists of TLC599, TLC590, TLC399 and TLC178 which are in clinical stage. Taiwan Liposome Company Ltd. is headquartered in Taipei City, Taiwan.

Company Info

Taiwan Liposome Company Ltd ADR

11TH FLOOR-1 YUANQU STREET NANGANG DISTRICT

TAIPEI CITY F5 11503

P: 886-2-2655-7377

CEO: Keelung Hong

TLC News

News Image5 months ago - TLCHighlights of Dr. David Hunter’s Oral Presentation at ACR’s Late Breaking Abstracts Session
News Image5 months ago - TLCHighlights of Dr. David Hunter’s Oral Presentation at ACR’s Late Breaking Abstracts Session

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Professor David Hunter, Florance and Cope Chair of Rheumatology at the...

News Image6 months ago - TLCTLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Session at ACR

Clinical benefits sustained to 24 weeks; second injection furthered benefits to 52 weeks

News Image6 months ago - TLCTLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Session at ACR

Clinical benefits sustained to 24 weeks; second injection furthered benefits to 52 weeks...

News Image2 years ago - Taiwan Liposome Company, Ltd.TLC Announces TLC599 Agreement with Endo

One of the largest deals seen in Taiwan’s biotech sector...

News Image2 years ago - Taiwan Liposome Company, Ltd.TLC BioSciences Announces Publication of TLC599 Phase II Results in Arthritis Research & Therapy

TLC599 reduces pain and improves function for up to 24 weeks, longer than existing intraarticular treatments, and significantly reduces oral medication...

TLC Twits

Here you can normally see the latest stock twits on TLC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example